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Abstract
Infantile haemangioma (IH), the most common neoplasm in infants, is a slowly resolving vascular tumour. Vascular
endothelial growth factor A (VEGF-A), which consists of both the pro- and anti-angiogenic variants, contributes
to the pathogenesis of IH. However, the roles of different VEGF-A variants in IH progression and its spontaneous
involution is unknown. Using patient-derived cells and surgical specimens, we showed that the relative level
of VEGF-A165b was increased in the involuting phase of IH and the relative change in VEGF-A isoforms may
be dependent on endothelial differentiation of IH stem cells. VEGFR signalling regulated IH cell functions and
VEGF-A165b inhibited cell proliferation and the angiogenic potential of IH endothelial cells in vitro and in vivo.
The inhibition of angiogenesis by VEGF-A165b was associated with the extent of VEGF receptor 2 (VEGFR2)
activation and degradation and Delta-like ligand 4 (DLL4) expression. These results indicate that VEGF-A variants
can be regulated by cell differentiation and are involved in IH progression. We also demonstrated that DLL4
expression was not exclusive to the endothelium in IH but was also present in pericytes, where the expression of
VEGFR2 is absent, suggesting that pericyte-derived DLL4 may prevent sprouting during involution, independently
of VEGFR2. Angiogenesis in IH therefore appears to be controlled by DLL4 within the endothelium in a VEGF-A
isoform-dependent manner, and in perivascular cells in a VEGF-independent manner. The contribution of VEGF-A
isoforms to disease progression also indicates that IH may be associated with altered splicing.
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Infantile haemangioma (IH) is the most common neo-
plasm of infancy [1,2]. The natural history of IH is a
rapid proliferating phase within the first 12 months of
life, followed by spontaneous involution over 7–10
years [2]. Haemangioma stem cells (HemSCs) are
believed to contribute to the pathogenesis of IH [3]
and have been hypothesized to be the parent cells
of haemangioma endothelial cells (HemECs), which
expand clonally in IH [4]. HemSCs proliferation and
vasculogenesis are VEGF-A-dependent [5] and
HemECs from some patients demonstrate a high
level of VEGF receptor 2 (VEGFR2) activation com-
pared with normal endothelial cells [6]. Thus, VEGF-A
appears to play pivotal roles in the pathogenesis of IH.
The VEGFA gene contains eight exons. Pre-mRNA
alternative splicing controls whether the mRNA con-
tains both exon 8a and 8b or exon 8b alone. The
final translated protein product is dependent on this
alternative splicing [7,8]. Proximal splicing of exon 8
leads to the translation of the first six amino acids
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited.
140 X Ye et al
in exon 8a, forming the pro-angiogenic VEGF-Axxxa
family. Distal splicing removes exon 8a from the tran-
script and results in the translation of the first six
amino acids in exon 8b, forming the anti-angiogenic
VEGF-Axxxb. Recently, an additional anti-angiogenic
VEGF-A variant, VEGF-Ax, generated by programmed
translational readthrough (PTR), has been reported [9].
The VEGF-A165a and VEGF-A165b isoforms in the pro-
and anti-angiogenic families have similar binding affini-
ties to VEGFR1 and VEGFR2 [10], but VEGF-A165b
does not bind to neuropilin-1 (Nrp-1), the co-receptor
for both VEGF receptors [11]. VEGF-Ax appears to
have similar properties to VEGF-A165b, in that it antag-
onizes VEGF-A165a-mediated VEGFR2 activation and
also does not bind to Nrp-1 [9].
VEGF-A165b, the most investigated isoform of the
anti-angiogenic variants, can inhibit tumour growth
and vascularization in xenograft models of colorectal,
prostate, melanoma and other cancers [12]. The roles
of the pro- and anti-angiogenic VEGF-A variants have
not been studied in IH. Due to the close association
of VEGF-A with IH, we set out to determine whether
VEGF-A isoforms contribute to the natural progres-
sion of IH and some of the associated mechanisms
underlying involution, and to test the hypothesis that
anti-angiogenic VEGF-A variants could contribute to IH
involution.
Materials and methods
Human tissues and immunohistochemistry
Formalin-fixed and paraffin-embedded human IH spec-
imens were biopsied or excised as part of clinical
care (and confirmed diagnostically with histological
morphology and characteristic GLUT-1 expression).
Human tissues were collected with ethical approval (No.
07/H0102/45). The stage of IHwas divided into prolifer-
ating or involuting phases. IH excisions from children up
to and including age 1 year were classified as proliferat-
ing, whilst excisions from children 3 years or older were
classified as involuting. If patient samples were derived
from children aged 1–3 years, the histology of the spec-
imens was examined and the stage of IH was confirmed
by pathologists.
Cell culture
IH stem cells (HemSCs), IH endothelial cells (HemECs)
and IH pericytes were isolated as described [3,4,13]
under the human subject protocol approved by the Com-
mittee on Clinical Investigation at Boston Children’s
Hospital. Informed consent was obtained according to
the Declaration of Helsinki. HemSCs and HemECs were
grown on fibronectin (0.3 μg/cm2; Millipore)-coated
plates in endothelial basal medium 2 (EBM-2; Lonza),
with 20% foetal bovine serum (FBS), EBM-2 Single-
Quot without hydrocortisone (Lonza), 2mM l-glutamine
and 1× antibiotic–antimycotic (100 U/ml penicillin,
100 μg/ml streptomycin, 250 ng/ml amphotericin B;
Gibco). This supplemented growth medium is complete
EGM-2. The HemSCs used were from donors 125,
129 and 133. HemECs were from donors 153, 158
and 159. IH pericytes were cultured on plates coated
with 0.5% gelatin and 0.3 μg/cm2 fibronectin in Dul-
becco’s modified Eagle’s medium (DMEM) GlutaMax,
low-glucose (Gibco), supplemented with 10% FBS and
2mM l-glutamine. Chinese hamster ovary (CHO) cells
and normal human dermal fibroblasts (NHDFs) were
maintained in RPMI and DMEM media respectively,
supplemented with 10% FBS and 2mM l-glutamine.
The cells were maintained with 5% CO2 at 37
∘C in a
humidified chamber.
Proliferating cell counts
Cells were plated at 1× 104 cells/cm2 on coverslips in
24-well plates. The cells were allowed to attach for 24 h
and treated for 36 h in complete EGM-2. The cells were
counted, differentiated or subjected to WST1 assay or
fixed with 4% paraformaldehyde, permeabilized with
PBS-Triton X (0.1%) and stained with Ki67 antibody
(Abcam ab16667) and DAPI. The total number of cells
and the number of cells positive for Ki67 in the nucleus
were counted in five fields of view.
Total cell count
Cells were plated at 1× 104 cells/cm2 on coverslips in
24-well plates. Cells were allowed to attach overnight
under normal growth conditions before administration
of treatments. One well was removed and its cells
fixed in 4% paraformaldehyde and stained with DAPI
nuclear stain every 24 h, and cell number was counted
microscopically in five random fields of view/coverslip.
Cell numbers were normalized to the number of cells
attached after 24 h.
WST-1 proliferation assay
Cells were plated at 3× 103 cells/well of a six-well plate.
The cells were left to attach in complete EGM-2 for
5 h. Themediumwas replaced with treatment containing
EGM-2 and grown for 36 h. Media and treatments were
removed and replaced with EBM-2 supplemented with
1% FBS and 10% WST-1 reagent (Roche Applied Bio-
science) and incubated under normal culture conditions
for 2 h.
Endothelial differentiation protocol
HemSCs were plated on fibronectin-coated plates at
2× 104 cells/cm2 in complete EGM-2 for 12 h. Hem-
SCs were then cultured in endothelial differentiating
medium [14] consisting of serum-free EBM-2, 1×
insulin–transferrin–selenium (Gibco), linoleic acid
at 1:5000 dilution, 60 μm ascorbic acid-2-phosphate,
1 μm dexamethasone (Sigma-Aldrich) and VEGF-B at
10 ng/ml (PeproTech) for 14 days. Fresh endothelial
differentiating medium was added every 2 days.
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Adenovirus
Chinese hamster ovary (CHO) cells were infected
with recombinant, replication-deficient adenoviruses
expressing GFP or sDLL4 under a CMV promoter
(Vector Biolabs) [15] at 100 MOI.
Protein expression
Immunofluorescence
Paraffin-embedded sections were dewaxed and rehy-
drated. Antigen retrieval was carried out in citrate
buffer (Sigma). Primary antibodies (PanVEGF-A, Santa
Cruz SC-152; VEGF-Axxxb, R&D Systems MAB1045;
VEGF-AXXXa [16]; CD31, Abcam ab28364; DLL4,
Abcam ab183532; human CD31, Cell Signaling 3528;
and NG2, Abcam ab83178) were incubated overnight
at 4 ∘C. Appropriate AlexaFluor secondary antibodies
(Molecular Probes) were incubated for 1 h at room tem-
perature. Five fields of view were recorded from each
patient’s section. All analyses were carried out masked,
ie patient groups were revealed only after the analy-
ses have been completed. Immunofluorescence images
were acquired using a Leica DMRB fluorescence micro-
scope fitted with an Olympus DP72 camera, using
Olympus CellSens software. For co-localization, images
were taken using a Leica SP8 confocal microscope and
LEICA LAS software.
Immunoblotting
Cells were plated in six-well plates and grown until
70–75% confluent. The cells were serum-starved with
EBM-2 medium for 12–16 h prior to VEGF-A treat-
ments, then lysed in lysis buffer (200mM NaCl, 75mM
Trizma base, 1mMEDTA, 1.5%Triton X, 0.75%Np-40,
15mM NaF and 1.5mM Na3VO4; Sigma-Aldrich) on
ice for 5min and subjected to standard immunoblotting
(antibody details and blotting conditions are described in
Supplementary materials and methods, see supplemen-
tary material).
VEGF-A ELISA
VEGF-A and VEGF-A165b protein levels were assessed
using human VEGF-A and VEGF-A165b DuoSet (R&D
Systems), following the manufacturer’s instructions.
Polymerase chain reaction (PCR)
RNA was extracted with TRI-reagent (Invitro-
gen); all materials, except primers, were purchased
from Promega; 1 μg RNA was DNase-treated and
reverse-transcribed with M-MLV reverse transcriptase.
PCR was carried out using a C1000 thermal cycler
(Bio-Rad). Reactions were carried out using the follow-
ing steps: 95 ∘C for 10min (hot start initiation), followed
by repeating 95 ∘C for 30 s, annealing temperature for
30 s and 72 ∘C for 30 s for up to 35 cycles. A final exten-
sion of 72 ∘C for 10min was then carried out. Amplified
products were run on an ethidium bromide agarose gel
and imaged using a Gel doc EZ system (Bio-Rad).
Quantitative PCR was carried out using lightcycler
480 SYBR Green master (Roche Applied Science)
and 0.25 μm gene specific primers, using a Lightcycler
480 real-time PCR thermal cycler (Roche Applied
Science). All reactions were carried out using the
protocol specified for PCR for 45 cycles; CT val-
ues< 35 were deemed acceptable. Human DLL4
primers were purchased from Qiagen (QT00081004);
other primer sequences are listed in Table S1 (see
supplementary material). Relative mRNA levels were
calculated, normalized to B2-microglobulin (B2M)
mRNA.
In vitro co-culture angiogenesis assay
NHDFs were grown on 19mm glass coverslips until
70–80% confluent. HemECs (3× 104) were plated on
the NHDF monolayer and allowed to settle for 6 h. The
medium was replaced with treatment containing EBM-2
supplemented with 4% FBS, and the treatment was
refreshed every 2 days for 10 days. The cells were fixed
with 70% ethanol and stained for VE-Cadherin (Abcam
ab33168) and the nuclei stained with DAPI. Images
were acquired from five fields of view at× 10 objective
magnification. Area of VE-Cadherin staining, tubule
length and number of branch points were measured and
normalized to the area of the field.
Murine haemangioma model
The murine model was produced as described [5], using
2× 106 HemSCs and 2× 106 HemECs resuspended in
200 μl Matrigel (Corning) and injected subcutaneously
into the left flank of CD1 nude mice (see supplemen-
tary material, Supplementary materials and methods,
for details of mouse housing conditions). The mice
were also weighed weekly and checked daily by an
experienced technician. Implants weremeasuredweekly
using Vernier callipers and the volume (V) was cal-
culated using the formula: V = ab2π/6, where a is the
longest diameter and b is the longest diameter perpen-
dicular to a. At termination, the explants were removed
and fixed with neutral-buffered formalin and embed-
ded in paraffin or cryopreserved in OCT. Three 5–7 μm
non-consecutive sections positioned 20–30 μm apart
were stained with haematoxylin and eosin (H&E), or
human-specific CD31 for microvessel density counting,
or with oil red O for fat deposition scoring. The analy-
ses were conducted without knowledge of the treatment
groups.
Statistical analyses
Data are presented as mean± standard error of the
mean (SE). Statistical analyses were carried out using
two-tailed Student’s t-test or ANOVA with Tukey’s post
hoc test where appropriate, unless stated otherwise;
p< 0.05 was considered significant.
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Results
Increase in the proportion of anti-angiogenic
VEGF-A isoforms coincides with IH involution
Immunofluorescence staining of human IH sections
for total VEGF-A showed no differences in VEGF-A
between the proliferating and the involuting phase of
IH (Figure 1A). In contrast, staining with VEGF-Axxxa-
and VEGF-Axxxb-specific antibodies (see supplemen-
tary material, Figure S1) [8,16] showed a significant
reduction in the level of the pro-angiogenic VEGF-Axxxa
isoform during involution (Figure 1B) and an increase in
the level of the anti-angiogenic VEGF-Axxxb isoforms
(Figure 1C). These data suggest that there is an alter-
ation in the ratio of VEGF-A isoforms, with a relative
increase in the proportion of anti-angiogenic variants
during involution.
VEGFR facilitates IH cell proliferation and changes
in VEGF-A isoforms in IH are associated
with differentiation of HemSCs into an endothelial
lineage
We questioned whether VEGFR signalling is involved
in IH cell functions. We used a commonly used VEGFR
inhibitor, PTK787 (see supplementary material, Figure
S2), and identified that proliferation of both HemSCs
and HemECs was significantly inhibited by PTK787 at
concentrations specific to VEGFRs (Figure 1D), sup-
porting the notion that active VEGF-A signalling is
important for IH.
CD133 was used to isolate multipotent HemSCs
from proliferating IH [3,5], which are lost during IH
involution (see supplementary material, Figure S3A),
consistent with previous observations [17]. HemSCs
express higher levels of VEGF-A compared with
NHDFs, HUVECs, HemEPCs [5] and, in this case,
also the HemECs (Figure 2A, D). Using primers span-
ning exons 7 and 8b, which distinguish the pro- and
anti-angiogenic VEGF-A variants (Figure 2B), we
found that the relative VEGF-A165b:VEGF-A165a ratio
was higher in HemECs when compared with HemSCs,
at both the cDNA and protein levels (Figure 2C, D).
VEGF-A165b was detected in HemSC protein lysates
by ELISA, but not in the mRNA by RT–PCR. This
may be explained by the competitive amplification
between VEGF-A165a and VEGF-A165b. Using recom-
binant VEGF-A cDNAs, we found that when the
VEGF-A165a variant concentration was> three-fold
higher than VEGF-A165b, VEGF-A165b detection was
completely lost by PCR (see supplementary material,
Figure S4). This may also explain the inconsistencies
in VEGF-A165b detection using PCR overall, as its
amplification is heavily influenced by the level of
VEGF-A165a.
Following observations that HemECs produce higher
levels of VEGF-A165b compared with HemSCs, we
hypothesized that the changes in VEGF-A isoforms
may be differentiation-dependent. We differentiated
HemSCs by treatment for 2 weeks with a different
member of the VEGF family, VEGF-B, a protocol
previously shown to induce an endothelial phenotype
via VEGFR1 activation [14]. We confirmed endothelial
differentiation by morphological changes, reduction of
the mesenchymal marker CD90 and also acquisition of
the endothelial marker VE-cadherin (see supplementary
material, Figure S5). The differentiated cells were
then returned to complete EGM-2 medium for 72 h
and we found that the differentiated cells produced
a lower level of VEGF-A using ELISA (Figure 2E;
p< 0.01) and western blotting (Figure 2G). Further-
more, we also found that the level of VEGF-A165b was
significantly increased compared with undifferentiated
cells, using ELISA (Figure 2 F; p< 0.05) and western
blotting (Figure 2G), suggesting that the differenti-
ation process may be at least partially responsible
for the differential VEGF-A isoform expression. An
additional band at a slightly higher molecular weight
than that of VEGF-A165a or VEGF-A165b was consis-
tently increased following differentiation (Figure 2G).
This band was detected using both total VEGF-A
and VEGF-A165b antibodies and may have been the
anti-angiogenic VEGF-Ax protein recently described
[9].
VEGF-B acts by signalling through VEGFR1. To
determine whether acute VEGFR1 activation could
induce VEGF-A165b expression directly, and hence
up-regulate VEGF-A165b prior to differentiation, we
stimulated HemSCs with VEGF-B for 36 h (insufficient
to result in differentiation). No significant changes
in VEGF-A, VEGF-A165b, SRSF2 expression (see
supplementary material, Figure S6A, B) or SRSF6
phosphorylation were observed (see supplementary
material, Figure S6C, D). SRSF2 and −6 are other
splice factors involved in VEGF-A splicing [18,19].
Only the phosphorylation of SRSF1, which has been
associated with proximal splicing of VEGF-A in cancer
cells and podocytes, was increased by VEGF-B over
this time period (see supplementary material, Figure
S6C, D).
VEGF-A165b inhibits VEGF-A165a mediated HemEC
angiogenesis and IH cell proliferation
We found VEGF-Axxxb was more localized to the struc-
tured endothelia with defined lumen structure, a typ-
ical feature of late proliferating and involuting phase
(Figure 3Aiv–ix) compared with the disorganized vas-
culature present in the early stages of the proliferating
phase (Figure 3Ai–iii); thus, the relative VEGF-A iso-
form ratios and distribution may have a direct functional
role in regulating IH angiogenesis/vasculogenesis.
We used VEGF-A165a as a positive control and
induced angiogenesis of HemECs in vitro, using
a co-culture angiogenesis assay. VEGF-A165b did
not induce HemECs angiogenesis and inhibited
VEGF-A165a-mediated tube formation, extension and
branching (Figure 3B–E). A previous study showed
that VEGF-A knockdown inhibits HemSCs proliferation
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Figure 1. Changes in VEGF-A isoform levels coincide with IH involution. (A) Tissue from proliferating phase (n= 8 patients) and involuting
phase (n= 11 patients) of IH were stained with a total VEGF-A antibody and showed no differences in total VEGF-A between the proliferating
and involuting phases of IH. (B) The area stained by a VEGF-Axxxa antibody and normalized to cell number showed a significant reduction of
VEGF-Axxxa in the involuting (n= 10) phase of IH compared with the proliferating (n= 5) phase (p< 0.05, two-tailed t-test). (C) VEGF-Axxxb
was increased in the involuting phase compared with the proliferating phase of haemangioma (p< 0.05, two-tailed t-test). (D) HemSCs and
HemECs were treated with increasing concentrations of PTK787, a VEGFR inhibitor, which significantly inhibited proliferation of HemSCs and
HemECs in a concentration-dependent manner (p< 0.001, one-way ANOVA, Bonferroni post hoc test; n= 5). Scale bar= 50 μm; *p< 0.05,
***p< 0.001; NS, not significant
and the vascularization of IH implants in vivo [5]. We
also obtained a similar result by treating the HemSCs
and cell implants with bevacizumab (see supplemen-
tary material, Figure S7A), suggesting the importance
of VEGF-A signalling in the growth and angiogene-
sis of this IH model. The effect of VEGF-A165b on
angiogenesis was also tested using this in vivo model,
and rhVEGF-A165b reduced the microvessel density
in the cell–Matrigel implants (Figure 4A, B). This
murine model has been described to acquire adipocytes
over time [3], a characteristic feature of human IH
pathology. The implants treated with recombinant
human VEGF-A165b (rhVEGF-A165b) also showed an
increase in fat deposition by oil red O staining (see
supplementary material, Figure S7B).
We identified that VEGFR inhibition using PTK787
[20] reduced proliferation of both HemECs and Hem-
SCs (Figure 1D). Therefore, we investigated whether
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Figure 2. HemECs and endothelial differentiation of HemSCs are associated withVEGF-A165b up-regulation. (A) Determination of mRNA
levels of VEGF-A in HemECs and HemSCs by RT–qPCR (n= 3 patients). (B) Diagram of RT–PCR primers spanning exons 7 and 8b, thus
amplifying both VEGF-A165a and VEGF-A165b. (C) RT–PCR for HemECs and HemSCs and plasmids containing recombinant cDNA for
VEGF-A165a and VEGF-A165b, or a mixture of equal amounts of both (n= 3 patients): MWM, molecular weight marker; −RT, no reverse
transcriptase. (D) Assessment of total VEGF-A and VEGF-A165b protein in lysate from HemECs and HemSCs, using sandwich ELISA (n= 3
patients). (E) Measurement of total VEGF-A in differentiated and undifferentiated HemSCs by ELISA. (F) Measurement of VEGF-A165b
in differentiated and undifferentiated HemSCs by ELISA. (G) Immunoblots of protein extracted from undifferentiated or differentiated
HemSCs, showing reduced intensity at band size corresponding to both VEGF-A165a and VEGF-A165b, using a total VEGF-A antibody (arrow)
(p< 0.05; n= 3), and increased intensity of band corresponding to VEGF-A165b molecular weight, using the VEGF-A165b antibody (p< 0.05;
n= 3) (arrow): an additional band (#) at a higher molecular weight than VEGF-A165a or VEGF-A165b was consistently detected following
differentiation of HemSCs; all analysed using two-tailed t-test
endogenous VEGF-A165b has an effect on IH cell prolif-
eration. Inhibition of VEGF-A165b was achieved using
a previously characterized antibody [8]. VEGF-A165b
neutralization increased the growth of HemECs, but not
HemSCs, over time compared with non-specific IgG
(Figure 4C, D). This suggests that VEGF-A165b may
act in an autocrine manner to limit the proliferation of
HemECs, which produce a relatively high proportion
of anti-angiogenic VEGF-A (Figure 2C, D). HemSCs
produce a lower proportion of VEGF-A165b compared
with HemECs (Figure 2C, D), and supplementing
the growth media with rhVEGF-A165b, significantly
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Figure 3. VEGF-A165b regulates sprouting angiogenesis in IH. (A) VEGF-Axxx-b, CD31 and nuclear (DAPI) staining of human IH sections:
histological features of proliferating IH move from early, barely discernable and mostly lumen-less microvessels (i–iii) to more structured
vessels late in the proliferating phase/early involuting phase (iv–vi) and finally microvessels with defined enlarged lumina in the involuting
phase (vii–ix); VEGF-Axxxb staining becomes more localized to the microvessels as the endothelia mature and organize into defined luminal
structures. (B) HemECs were treated with VEGF-A165a, VEGF-A165b or both on a monolayer of NHDFs, using an in vitro angiogenesis assay:
HemECs were stained with VE-cadherin. (C–E) Quantification of (B): 2.5 nM VEGF-A165a induced tube area (C), length (D) and branching (E),
compared with the untreated, 2.5 nM VEGF-A165b or HemECs treated with 2.5 nM VEGF-A165a and VEGF-A165b (n= 3; p< 0.001, one-way
ANOVA). Scale bars= 100 μm
inhibited their proliferation (measured using Ki67 as
a proliferation marker) (Figure 4E, F). The inhibitory
effect of both VEGF-A165b and bevacizumab on Hem-
SCs, but not HemECs, was further confirmed using the
WST-1 proliferation assay (see supplementary material,
Figure S8A, B). This suggests that VEGF-A165b from
other sources, such as those produced by HemECs, may
inhibit HemSCs proliferation in a paracrine manner,
displaying an intricate system of proliferation and
angiogenic control between the two different cell types.
Pro- and anti-angiogenic VEGF-A isoforms
differentially regulate VEGFR2 activation,
degradation and downstream signalling
VEGF-A mediates the proliferation and angiogene-
sis of endothelial cells via VEGFR2[21]. Whilst the
signalling of VEGFR2 stimulated by VEGF-A165a
and VEGF-A165b has been investigated in human
microvascular endothelial cells (HMVECs), it has not
been conducted in HemECs, an endothelial cell with
progenitor-like gene expression and properties [22], nor
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 239: 139–151
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Figure 4. VEGF-A165b inhibits angiogenesis in a murine model of IH and inhibits IH cell proliferation in vitro. (A) HemEC–HemSC–Matrigel
implants treated with 15 μg s.c. rhVEGF-A165b (n= 5) or saline (n= 8) twice weekly for 2 weeks. The implants were sectioned, stained
with H&E and the blood-filled lumina were counted (arrow). Implants treated with rhVEGF-A165b showed lower microvessel density
than saline-treated ones (n= 8; p< 0.01). (B) Implants treated with rhVEGF-A165b (n= 6) formed fewer human CD31+ microvessels than
saline-treated ones (n= 8; p< 0.001, two-tailed Student’s t-test). (C, D) HemSCs (C) and HemECs (D) were treated with 1 μg/ml VEGF-A165b
neutralizing antibody for 24–96 h in complete EGM-2: cell numbers at 48, 72 and 96 h were normalized to the number of cells at 24 h
(n= 3; p< 0.05, two-way ANOVA, Bonferroni post hoc test compared with IgG). (E) HemECs were treated in complete EGM-2 with specified
concentrations of rhVEGF-A165b for 48 h; cells were stained for DAPI and Ki67. (F) Quantification of (E): the percentage of proliferating
HemECs was unaffected by 5 or 10 nM rhVEGF-A165b; the percentage of proliferating HemSCs was reduced when cells were treated with
10 nM VEGF-A165b compared with untreated ones. Scale bars= 50 μm; *p< 0.05, **p< 0.01, ***p< 0.01; NS, not significant
in HemSCs. We found that both HemSCs and HemECs
respond, in a similar manner to the VEGF-A isoforms,
as normal endothelial cells, wherein VEGF-A165a
activates VEGFR2 as well as downstream signalling,
which is important for IH cell proliferation, and that this
could be blocked with VEGF-A165b (Figure 5A, B; see
also supplementary material, Figure S9). Others have
demonstrated that the lack of Nrp-1 signalling promotes
VEGFR2 degradation [23], and that VEGF-A165b,
which does not bind to Nrp-1 [11], promotes
VEGFR2 degradation and/or prevents recycling of the
receptor. In HemECs, both VEGF-A165a and
VEGF-A165b induced a reduction of VEGFR2 over
time. However, the reduction caused by VEGF-A165b
stimulation was more prominent than that induced
byVEGF-A165a with prolonged stimulations (Figure 5C,
D), suggesting that VEGF-A165b may preferentially
direct VEGFR2 for degradation, as opposed to recy-
cling.
The Notch–Delta signalling pathway is one of the
most studied pathways in sprouting angiogenesis.
Whilst Delta-like ligand 4 (DLL4) expression can be
induced by VEGF-A165a in normal endothelial cells
[24] and in HemECs (Figure 5E, F), VEGF-A165b did
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 239: 139–151
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
VEGF-A variants and DLL4 in infantile haemangioma 147
Figure 5. VEGFR2 signalling, degradation and downstream targets are differentially regulated by VEGF-A isoforms. Cells were serum-starved
prior to treatment with 2.5 nM VEGF-A165a, VEGF-A165b or both. (A, B) VEGF-A165a induced VEGFR2 signalling and downstream activation
of ERK1/2 in both HemSCs and HemECs; VEGF-A165b weakly activated VEGFR2 and ERK1/2 in HemSCs and HemECs; VEGF-A165b inhibited
VEGF-A165a-mediated VEGFR2 and ERK1/2 phosphorylation in both HemSCs and HemECs. (C) HemECs were treated with 2.5 nM VEGF-A165a
and VEGF-A165b and protein extracted at the time points shown. (D) Quantification of (C): treatment with VEGF-A165b, but not VEGF-A165a,
significantly reduced VEGFR2 levels; n= 3; p< 0.05, one-way ANOVA; *p< 0.05 compared with VEGF-A165b; #p< 0.05 compared with
time 0. (E) HemECs were treated as above and RNA extracted and subjected to RT–qPCR for DLL4 expression; p< 0.001, ANOVA. (F)
VEGF-A165a-induced DLL4 expression compared with untreated (n= 3; p< 0.05, one-way ANOVA); VEGF-A165b, alone or together with
VEGF-A165a, did not induce DLL4 expression at the protein level; *p< 0.05, **p< 0.01, ***p< 0.01; NS, not significant
not induce DLL4 expression to the same extent and
was able to ameliorate VEGF-A165a-mediated DLL4
up-regulation in HemECs (Figure 5E, F). We tested
whether activation of Notch signalling using the soluble
portion of DLL4 (sDLL4), previously described [25],
can affect the angiogenic potential of HemECs. We
overexpressed sDLL4 in CHO cells (see supplementary
material, Figure S10), using an adenovirus vector, and
used the conditioned medium of the infected cells to
treat the HemECs in the in vitro angiogenesis assay.
sDLL4 blocked the angiogenic tube formation, exten-
sion and branching ability of HemECs under all of the
conditions tested, including those that were stimulated
with VEGF-A165a (Figure 6A–D).
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Figure 6. Extra-endothelial DLL4 signalling inhibits HemECs angiogenesis. (A) HemECs were co-cultured with normal human dermal
fibroblasts and treated with conditioned media from CHO cells, untransduced (negative) or transduced with GFP (Ad.GFP) or sDLL4
adenovirus (ad.DLL4) and VEGF-A165a or VEGF-A165b; the cells were then stained for VE-cadherin. (B–D) Quantifications of (A): VEGF-A165a,
not VEGF-A165b, induced endothelial tube extension, branching and coverage in the assay (n= 3; p< 0.001); conditioned media from CHO
cells infected with ad.sDLL4 inhibited the in vitro angiogenic potential of HemECs, irrespective of the VEGF-A isoforms present (n= 3;
p< 0.001, two-way ANOVA) compared with ad.GFP or untransduced conditioned medium. (E) Sections of IH were stained for NG2 and
DLL4: typical stainings of proliferating and involuting IH are shown; relatively low NG2 staining was present in the proliferating phase; in
the involuting phase, a relatively high proportion of DLL4 staining co-localized with NG2-positive cells in the more organized vasculature. (F)
DLL4 protein expression was found in HemECs and IH pericytes, but VEGFR2 protein was undetectable in IH pericytes. Scale bars= 100 μm
DLL4 up-regulation normally occurs in the angio-
genic tip cells of endothelium [26]. However, it is
challenging to define angiogenic tip cells in IH sections
and we see only a moderate level of co-localization
between DLL4 and microvessels (marked with CD31)
in the proliferating phase (see supplementary material,
Figure S11i–iii). In the involuting phase of IH, we
expected a loss or reduction of DLL4 staining due to
termination of excessive angiogenesis. However, DLL4
staining was clearly present in the involuting phase, par-
ticularly prominent around microvessels with defined
luminal structures, and was found closely associated
with the perivascular regions that do not co-localize with
CD31 (see supplementary material, Figure S11iv–vi)
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and co-localized with NG2, a pericyte marker, which
was less abundant in the proliferating phase (Figure 6E).
IH pericytes may regulate angiogenesis via DLL4
DLL4 therefore appears to be generated from IH per-
icytes. These cells have been previously described
as having similar levels of VEGF-A expression [13]
and we were able to confirm this (see supplementary
material, Figure S12). However, we were unable to
detect VEGFR2 protein expression in the IH pericytes
(Figure 6 F), although DLL4 was expressed by, and was
stronger in, pericytes from involuting lesions than pro-
liferating ones (Figure 6 F). This suggests that, unlike
in endothelial cells, DLL4 in IH pericytes is unlikely to
be regulated by VEGFR2, but is increased in involuting
lesions.
Discussion
In this study we have shown an increase in the pro-
portion of the anti-angiogenic VEGF-A165b during
the involuting phase of IH. This phenomenon is at
least partially governed by the loss of CD133+ high
VEGF-Axxxa-expressing HemSCs and its differentiation
into an endothelial phenotype, a process that has not
previously been shown to regulate VEGF-A variants.
With the recent description of a novel anti-angiogenic
VEGF-A isoform, VEGF-Ax [9], it is possible that both
alternative splicing and post-translational read-through
could be regulated in this manner.
VEGFR1 mediates HemSCs differentiation into
endothelial cells [14] and therefore its activation might
also be responsible for the changes in VEGF-A iso-
forms. Whilst acute VEGF-B induced phosphorylation
of SRSF1, a splice factor that is often associated with
VEGF-A splicing in podocytes and in cancer cells
[18], no changes in total VEGF-A or VEGF-A165b
were observed. However, the relative expression and
phosphorylated states of the other members of the SRSF
family are likely to have a role in regulating VEGF-A
splicing, even in the event of SRSF1 phosphorylation.
The data suggest that acute VEGFR1 activation is
insufficient to drive VEGF-A splicing and that the
observations we made may be due to the long-term
cellular reorganization and acquisition of a different
cellular phenotype initiated by VEGFR1. The differ-
entiation process affects a large number of genes and
further investigations using a proteomics and RNA
sequencing approach will be able to provide a greater
overview of alternative splicing changes, as well as
identification of splice factors that may regulate these
events.
We found that VEGF-A165b in IH is closely associ-
ated with organized vasculature with defined luminal
structures, where VEGF-A165b is capable of inhibit-
ing sprouting angiogenesis and may promote the
stabilization of microvessels. VEGF-A165b inhibited
VEGF-A165a-induced angiogenesis of HemECs in
vitro, an effect that was also observed in vivo. Further-
more, endogenously produced VEGF-A165b can inhibit
HemECs proliferation, a cell population that produces
a relatively high proportion of the anti-angiogenic
VEGF-A isoforms. It would appear that the endoge-
nously produced VEGF-A165b is insufficient to inhibit
growth of HemSCs, which predominantly produce the
pro-angiogenic VEGF-A variants. However, a high
level of VEGF-A165b is inhibitory to HemSCs pro-
liferation. Thus, an intricate autocrine and paracrine
effect of VEGF-A165b may exist between the HemSCs
and HemECs. We have demonstrated that the mainte-
nance of VEGFR signalling is important for HemSCs
and HemECs proliferation. The anti-proliferative
and anti-angiogenic effects of VEGF-A165b may be
attributed to the fact that VEGF-A165b is a weak agonist
of VEGFR2 and ameliorates VEGF-A165a-mediated
VEGFR2 activation and downstream signalling, pro-
moting the degradation of VEGFR2 [11,23] as well
as lack of DLL4 induction, an important factor in the
establishment of endothelial tip cells. Whilst high DLL4
in endothelial tip cells and low DLL4 in the endothelial
stalk cells promotes angiogenesis [26], indiscriminate
Notch activation in the endothelium is inhibitory to
angiogenesis; such is the case with the use of sDLL4.
Thus, if VEGF-A165b prevents DLL4 up-regulation in
endothelial cells, then this is likely to prevent tip cell
formation and sprouting in involuting cells. However,
DLL4 was expressed in involuting lesions, but within
the pericytes. This suggests that mural cells may also
inhibit sprouting angiogenesis via the Notch–Delta
signalling pathway in IH. Unlike endothelial cells,
VEGFR2 is not expressed by the IH pericytes and,
therefore, it is unlikely that DLL4 is regulated in the
same manner between HemECs and IH pericytes.
Extra-endothelial DLL4 in the form of sDLL4 inhibited
HemECs angiogenesis in the absence of VEGF-A165a;
thus, it is possible that DLL4 from perivascular cells
may cooperate with VEGF-A165b to regulate IH invo-
lution – VEGF-A165b prevents VEGFR2 signalling in
endothelial cells that express it, and pericyte DLL4
inhibits sprouting in cells that are not inhibited by
neighbouring DLL4 expression (see supplementary
material, Figure S13).
In conclusion, we have identified that IH involu-
tion is associated with an increase in the proportion
of VEGF-A165b, which is associated with the dif-
ferentiation of stem cells, a previously undescribed
event. VEGF-A165b, the most investigated of the
anti-angiogenic variants, plays a key role in regulating
both cell proliferation and disrupting/preventing the
up-regulation of DLL4 and establishment of the tip and
stalk endothelial phenotype, demonstrating for the first
time the relative proportion of pro- and anti-angiogenic
VEGF-A isoforms as a potential mediator of IH invo-
lution. We identified that perivascular cells can express
DLL4 in IH, and we hypothesize that it may cooperate
with anti-angiogenic VEGF-A isoforms to regulate IH
involution.
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